skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Pegylated Liposomal Doxorubicin Hydrochloride (Code C1555)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Pegylated Liposomal Doxorubicin Hydrochloride

Definition: A liposome-encapsulated preparation of the hydrochloride salt of the anthracycline antineoplastic antibiotic doxorubicin. Doxorubicin intercalates between DNA base pairs, thereby hinders the movement of replication machinery along DNA strands, as well as blocks the activity of topoisomerase II during replication. As a result, this agent causes DNA adducts formation, renders single- and double-stranded DNA breakages that induce DNA repair and or apoptotic processes. Doxorubicin also generates reactive oxygen species that leads to cytotoxicity secondary to lipid peroxidation of cell membrane lipids. Liposomal delivery of doxorubicin HCl improves drug penetration into tumors and decreases drug clearance, thereby increasing the duration of therapeutic drug effects. A liposomal formulation of doxorubicin also modulates toxicity, specifically the cardiac effects commonly seen with anthracycline antitumor drugs.

NCI-GLOSS Definition: A form of the anticancer drug doxorubicin that is contained in very tiny, fat-like particles. It may have fewer side effects and work better than doxorubicin. Doxil is used to treat ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma in patients whose disease has not gotten better after treatment with other anticancer drugs. It may be used together with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Doxil is a type of anthracycline antitumor antibiotic.

Display Name: Pegylated Liposomal Doxorubicin Hydrochloride

Label: Pegylated Liposomal Doxorubicin Hydrochloride

NCI Thesaurus Code: C1555 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1522690  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
(8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-tri-hydroxy-1-methoxy-5,12-naphthacenedione Hydrochloride
Doxorubicin HCl Liposome
doxorubicin hydrochloride liposome
Doxorubicin Hydrochloride Liposome
Liposomal Adriamycin
liposomal doxorubicin hydrochloride
Liposomal Doxorubicin Hydrochloride
Liposomal-Encapsulated Doxorubicin
Pegylated Doxorubicin HCl Liposome
Pegylated Liposomal Doxorubicin Hydrochloride
S-Liposomal Doxorubicin
Stealth Liposomal Doxorubicin
TLC D-99

External Source Codes: 
NSC Code 712227 (see NCI DTP info)
PDQ Closed Trial Search ID 39424
PDQ Open Trial Search ID 39424 (check for NCI PDQ open clinical trial info)
UMLS CUI C1522690

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Refractory metastatic carcinoma of the ovary; AIDS-related Kaposi's sarcoma; breast cancer; relapsed/refractory multiple myeloma (with bortezomib).
code C1555
Contributing_Source CTRP
Legacy_Concept_Name Doxorubicin_Hydrochloride_Liposome
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom